|
|
| Line 1: |
Line 1: |
| {{DrugProjectFormSinglePage
| |
| |authorTag={{Y.A}};
| |
| |genericName=generic name
| |
| |aOrAn=a
| |
| |drugClass=Acetylcholine release inhibitor, Adrenergic receptor agonist
| |
| |indicationType=(type of indication of drug)
| |
| |indication=a list of indications, separated by commas.
| |
| |hasBlackBoxWarning=Yes
| |
| |adverseReactions=a list of adverse reactions, separated by commas.
| |
| |blackBoxWarningTitle=Warning Title
| |
| |blackBoxWarningBody=<i><span style="color:#FF0000;">Condition Name:</span></i> (Content)
| |
| |fdaLIADAdult======Condition 1=====
| |
|
| |
|
| * Dosing Information
| |
|
| |
|
| :* (Dosage)
| | {{drugbox-mab |
| | | | image = |
| =====Condition 2=====
| | | source = [[recombinant]] |
| | | | target = [[CD20]] |
| * Dosing Information
| |
| | |
| :* (Dosage)
| |
| |offLabelAdultGuideSupport======Condition 1=====
| |
| | |
| * Developed by: (Organisation)
| |
| | |
| * Class of Recommendation: (Class) (Link)
| |
| | |
| * Strength of Evidence: (Category A/B/C) (Link)
| |
| | |
| * Dosing Information/Recommendation
| |
| | |
| :* (Dosage)
| |
| | |
| =====Condition 2=====
| |
| | |
| * Developed by: (Organisation)
| |
| | |
| * Class of Recommendation: (Class) (Link)
| |
| | |
| * Strength of Evidence: (Category A/B/C) (Link)
| |
| | |
| * Dosing Information/Recommendation
| |
| | |
| :* (Dosage)
| |
| |offLabelAdultNoGuideSupport======Condition 1=====
| |
| | |
| * Dosing Information
| |
| | |
| :* (Dosage)
| |
| | |
| =====Condition 2=====
| |
| | |
| * Dosing Information
| |
| | |
| :* (Dosage)
| |
| | |
| =====Condition 3=====
| |
| | |
| * Dosing Information
| |
| | |
| :* (Dosage)
| |
| |fdaLIADPed======Condition 1=====
| |
| | |
| * Dosing Information
| |
| | |
| :* (Dosage)
| |
| | |
| =====Condition 2=====
| |
| | |
| * Dosing Information
| |
| | |
| :* (Dosage)
| |
| |offLabelPedGuideSupport======Condition 1=====
| |
| | |
| * Developed by: (Organisation)
| |
| | |
| * Class of Recommendation: (Class) (Link)
| |
| | |
| * Strength of Evidence: (Category A/B/C) (Link)
| |
| | |
| * Dosing Information/Recommendation
| |
| | |
| :* (Dosage)
| |
| | |
| =====Condition 2=====
| |
| | |
| * Developed by: (Organisation)
| |
| | |
| * Class of Recommendation: (Class) (Link)
| |
| | |
| * Strength of Evidence: (Category A/B/C) (Link)
| |
| | |
| * Dosing Information/Recommendation
| |
| | |
| :* (Dosage)
| |
| |offLabelPedNoGuideSupport======Condition 1=====
| |
| | |
| * Dosing Information
| |
| | |
| :* (Dosage)
| |
| | |
| =====Condition 2=====
| |
| | |
| * Dosing Information
| |
| | |
| :* (Dosage)
| |
| | |
| =====Condition 3=====
| |
| | |
| * Dosing Information
| |
| | |
| :* (Dosage)
| |
| |contraindications=CONTRAINDICATIONS
| |
| |warnings======Conidition 1=====
| |
| | |
| (Description)
| |
| | |
| =====Conidition 2=====
| |
| | |
| (Description)
| |
| | |
| =====Conidition 3=====
| |
| | |
| (Description)
| |
| |clinicalTrials=======Central Nervous System======
| |
| | |
| : (list/description of adverse reactions)
| |
| | |
| ======Cardiovascular======
| |
| | |
| : (list/description of adverse reactions)
| |
| | |
| ======Respiratory======
| |
| | |
| : (list/description of adverse reactions)
| |
| | |
| ======Gastrointestinal======
| |
| | |
| : (list/description of adverse reactions)
| |
| | |
| ======Hypersensitive Reactions======
| |
| | |
| : (list/description of adverse reactions)
| |
| | |
| ======Miscellaneous======
| |
| | |
| : (list/description of adverse reactions)
| |
| | |
| =====Condition 2=====
| |
| | |
| ======Central Nervous System======
| |
| | |
| : (list/description of adverse reactions)
| |
| | |
| ======Cardiovascular======
| |
| | |
| : (list/description of adverse reactions)
| |
| | |
| ======Respiratory======
| |
| | |
| : (list/description of adverse reactions)
| |
| | |
| ======Gastrointestinal======
| |
| | |
| : (list/description of adverse reactions)
| |
| | |
| ======Hypersensitive Reactions======
| |
| | |
| : (list/description of adverse reactions)
| |
| | |
| ======Miscellaneous======
| |
| | |
| : (list/description of adverse reactions)
| |
| |postmarketing=(Description)
| |
| |drugInteractions=* Drug 1
| |
| * Drug 2
| |
| * Drug 3
| |
| * Drug 4
| |
| * Drug 5
| |
| | |
| =====Drug 1=====
| |
| | |
| (Description)
| |
| | |
| =====Drug 2=====
| |
| | |
| (Description)
| |
| | |
| =====Drug 3=====
| |
| | |
| (Description)
| |
| | |
| =====Drug 4=====
| |
| | |
| (Description)
| |
| | |
| =====Drug 5=====
| |
| | |
| (Description)
| |
| |useInPregnancyFDA=(Description)
| |
| |useInLaborDelivery=(Description)
| |
| |useInNursing=(Description)g
| |
| |useInPed=(Description)
| |
| |useInGeri=(Description)
| |
| |useInGender=(Description)
| |
| |useInRace=(Description)
| |
| |useInRenalImpair=(Description)
| |
| |useInHepaticImpair=(Description)
| |
| |useInReproPotential=(Description)
| |
| |useInImmunocomp=(Description)
| |
| |othersTitle=Others
| |
| |useInOthers=(Description)
| |
| |administration=(Oral/Intravenous/etc)
| |
| |monitoring======Condition 1=====
| |
| | |
| (Description regarding monitoring, from ''Warnings'' section)
| |
| | |
| =====Condition 2=====
| |
| | |
| (Description regarding monitoring, from ''Warnings'' section)
| |
| | |
| =====Condition 3=====
| |
| | |
| (Description regarding monitoring, from ''Warnings'' section)
| |
| | |
| |overdose====Acute Overdose===
| |
| | |
| ====Signs and Symptoms====
| |
| | |
| (Description)
| |
| | |
| ====Management====
| |
| | |
| (Description)
| |
| | |
| ===Chronic Overdose===
| |
| | |
| ====Signs and Symptoms====
| |
| | |
| (Description)
| |
| | |
| ====Management====
| |
| | |
| (Description)
| |
| |drugBox={{Drugbox2
| |
| | verifiedrevid =
| |
| | IUPAC_name =
| |
| | image = | |
| | drug_name = | |
| | |
| <!--Clinical data-->
| |
| | tradename =
| |
| | MedlinePlus =
| |
| | licence_US =
| |
| | pregnancy_AU =
| |
| | pregnancy_US =
| |
| | legal_status =
| |
| | routes_of_administration =
| |
| | |
| <!--Pharmacokinetic data-->
| |
| | bioavailability =
| |
| | metabolism =
| |
| | elimination_half-life =
| |
| | excretion =
| |
| | |
| <!--Identifiers-->
| |
| | CAS_number_Ref = | |
| | CAS_number = | | | CAS_number = |
| | ATC_prefix = | | | ATC_prefix = |
| | ATC_suffix = | | | ATC_suffix = |
| | PubChem = | | | PubChem = |
| | IUPHAR_ligand =
| |
| | DrugBank_Ref =
| |
| | DrugBank = | | | DrugBank = |
| | ChemSpiderID_Ref = | | | chemical_formula = |
| | ChemSpiderID =
| |
| | UNII_Ref =
| |
| | UNII =
| |
| | KEGG_Ref =
| |
| | KEGG =
| |
| | ChEBI_Ref =
| |
| | ChEBI =
| |
| | ChEMBL_Ref =
| |
| | ChEMBL =
| |
| | |
| <!--Chemical data-->
| |
| | C= | H= | N= | O=
| |
| | molecular_weight = | | | molecular_weight = |
| | smiles = | | | bioavailability = |
| | InChI = | | | protein_bound = |
| | InChIKey = | | | metabolism = |
| | StdInChI_Ref = | | | elimination_half-life = |
| | StdInChI = | | | excretion = |
| | StdInChIKey_Ref = | | | pregnancy_AU = |
| | StdInChIKey = | | | pregnancy_US = |
| | melting_point = | | | pregnancy_category = |
| | | legal_AU = |
| | | legal_CA = |
| | | legal_UK = |
| | | legal_US = |
| | | legal_status = |
| | | routes_of_administration = |
| }} | | }} |
| |mechAction=(Description) | | '''Ocrelizumab''' is a [[Humanize|humanized]] anti CD20 [[monoclonal antibody]]. It targets mature B lymphocytes. As of May 2007 it is in clinical trials (phase III) for rheumatoid arthritis, multiple sclerosis and lupus erythematosus. |
| |structure=(Description with picture)
| | {{monoclonal-antibody-stub}} |
| |PD=(Description)
| | {{immunosuppressants}} |
| |PK=(Description)
| | {{humanizedmonoclonals}} |
| |nonClinToxic=(Description)
| |
| |clinicalStudies======Condition 1=====
| |
| | |
| (Description)
| |
| | |
| =====Condition 2=====
| |
|
| |
|
| (Description)
| | [[Category:Monoclonal antibodies]] |
| | | {{WikiDoc Help Menu}} |
| =====Condition 3=====
| | {{WikiDoc Sources}} |
| | |
| (Description)
| |
| |howSupplied=(Description)
| |
| |storage=(Description)
| |
| |packLabel=zzz
| |
| |fdaPatientInfo=(Patient Counseling Information)
| |
| |nlmPatientInfo=(Link to patient information page)
| |
| |lookAlike=* (Paired Confused Name 1a) — (Paired Confused Name 1b)
| |
| * (Paired Confused Name 2a) — (Paired Confused Name 2b)
| |
| * (Paired Confused Name 3a) — (Paired Confused Name 3b)
| |
| |brandNames=
| |
| |drugShortage=Drug Shortage
| |
| | |
| }} | |
